Role of coagulation parameters and inflammatory biomarkers in coronavirus disease 2019 patients: A demystifying endeavor

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) globally known as COVID-19 is a heterogeneous disease caused by the severe acute respiratory syndrome coronavirus 2. COVID-19 patients having severe disease and are critically ill are more prone to have abnormal coagulation prolife. It may lead to thromboinflammation in severe conditions. AIM: The aim is to evaluate the utility of coagulation parameters and inflammatory biomarkers in COVID-19 patients in the study conducted for 6 months duration. MATERIALS AND METHODS: It was a retrospective observational study conducted from April 2021 to September 2021 in a rural tertiary care referral Institute. Available data of the baseline values of coagulation parameters (platelet count [PLC], prothrombin time [PT], international normalized ratio [INR], partial thromboplastin time [PTT] and D-dimer) and inflammatory markers (C-reactive protein [CRP], serum lactate dehydrogenase [LDH], and serum ferritin) were evaluated with respect to the clinical severity of the disease and also the survival status of COVID-19 patients. RESULTS: One hundred and fifty-five cases of COVID-19-positive patients were analyzed. PT, INR, PTT, D-dimer, CRP, LDH, and ferritin had higher mean in severe cases than the nonsevere cases. PLC had higher mean in the severe cases than the nonsevere cases. PT, INR, PTT, D-dimer, CRP, LDH and ferritin had higher mean in nonsurvivors than the survivors. PLC had lower mean in nonsurvivors than the survivors. CONCLUSION: Baseline values of PT, INR, PTT, D-dimer, LDH, and ferritin may be considered reliable indicators of severity of COVID-19 disease. Baseline values of D-dimer, LDH, and ferritin may be considered a reliable indicator of survival of patients suffering from COVID-19 infection.

Keywords

• coronavirus disease 2019
• disease
• severe acute respiratory syndrome
• survivors